Shanghai juntop biosciences co. ltd
Webb31 mars 2024 · SHANGHAI, China, March 31, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading …
Shanghai juntop biosciences co. ltd
Did you know?
Webb3 dec. 2024 · Shanghai Junshi Biosciences : VOLUNTARY ANNOUNCEMENT - ENTERING INTO THE DRUG DEVELOPMENT AND LICENSE CONTRACT WITH HANGZHOU DAC MarketScreener Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make … Webb6 apr. 2024 · Shanghai Junshi Biosciences Co., Ltd. Announces Three Phase I Clinical Study Results on VV116 Tablet. The board of directors of Shanghai Junshi Biosciences …
WebbShanghai Junshi Biosciences Co., Ltd. operates as a biopharmaceutical company. The Company develops and sells small molecule drugs, antibody drug conjugates, and other … http://website.shanghaijunshi.wisdomir.com/en/index.php
Webb16 mars 2024 · Der Vorstand von Shanghai Junshi Biosciences Co., Ltd. gab bekannt, dass drei klinische Studienergebnisse der Phase I zu VV116 Tablette , einem oralen nukleosidanalogen Anti-SARS-CoV-2 Medikament, das... 5 Februar 2024 Webb16 dec. 2024 · Shanghai JunTop Biosciences Co., Ltd.* (hereinafter referred to as “JunTop Biosciences”), a wholly-owned subsidiary of Shanghai Junshi Biosciences Co., Ltd.* …
WebbCompany Information. Principal Place of Business in Hong Kong. Level 54, Hopewell Centre 183 Queen’s Road East Hong Kong. Stock Code. 1877.
WebbShanghai Junshi Bioscience Co Ltd Country. China. Address. Shanghai, Shanghai, 201203. Phone Number. 86 21 61058800. Website. www.junshipharma.com jemma skeatWebb18 apr. 2024 · The board (the “Board”) of directors (the “Directors ”) of the Company is pleased to announce that the results of the preclinical in vivo efficacy study of VV116 tablet (“VV116”), an oral nucleoside analog anti-SARS-CoV-2 drug jointly developed by Shanghai JunTop Biosciences Co., Ltd.* (上 lakai clearance saleWebbShanghai JunTop Biosciences Co., Ltd. (《關於上海君拓生物醫藥科技有限公司之 增資協議》) (hereinafter referred to as the “Agreement”) with Round A Investors, pursuant to which, JunTop Biosciences intends to increase its registered capital by RMB140,366,972, and Round A Investors propose to subscribe for the jemma shieldWebb11 dec. 2024 · >SHANGHAI, China, December 10, 2024 (GLOBE NEWSWIRE) – Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the updated preliminary … jemma sargeantWebb31 mars 2024 · SHANGHAI, China, March 31, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading … jemma singerWebbCompany Information. Principal Place of Business in Hong Kong Level 54, Hopewell Centre 183 Queen’s Road East Hong Kong. Stock Code 1877. ... SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE ADDITION OF A NEW IMPLEMENTATION ENTITY FOR INVESTMENT PROJECTS. Investor Relations Corporate Information Announcements jemmas cupcakesWebb31 mars 2024 · SHANGHAI, China, March 31, 2024 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced financial results for the full … jemma skidmore